Law Firm Investigates Pacira BioSciences Sale to Viatris
Monteverde & Associates PC has launched an investigation into the sale of Pacira BioSciences to Viatris. The inquiry aims to determine if Pacira shareholders will receive a fair price for the company.
Law firm Monteverde & Associates PC announced on October 11, 2026, that it is investigating Pacira BioSciences, Inc. (NASDAQ: PCRX). The investigation concerns the company's proposed sale to Viatris Inc.
Under the terms of the agreement, Pacira shareholders are expected to receive $36.50 in cash per share. Monteverde & Associates PC, specializing in shareholder class actions, seeks to assess whether this offer represents a fair valuation and adequately protects the interests of Pacira's investors.
The firm, headquartered in New York's Empire State Building, has a history of recovering significant sums for shareholders and has been recognized by ISS Securities Class Action Services.
Pacira BioSciences shareholders with concerns or further information regarding the transaction are encouraged to contact Monteverde & Associates PC. The firm states its services are free and without obligation to shareholders.